Equilin - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (2)

Identification

Name

Equilin

Accession Number

DB02187 (EXPT01355)

Type

Small Molecule

Groups

Approved

Description

An estrogenic steroid produced by horses. It has a total of four double bonds in the A- and B-ring. High concentration of euilin is found in the urine of pregnant mares. [PubChem]

Equilin is one of the estrogens present in the mixture of estrogens isolated from horse urine and marketed as Premarin. Premarin became the most commonly used form of estrogen for hormone replacement therapy in the United States of America. Estrone is the major estrogen in Premarin (about 50%) and equilin is present as about 25% of the total. Estrone is a major estrogen that is normally found in women. Equilin is not normally present in women, so there has been interest in the effects of equilin on the human body. [Wikipedia]

The estrogens in Premarin are present mainly as "conjugates", modified chemical forms in which the active estrogen is coupled to another chemical group such as sulfate. Estrone sulfate is usually the major form of estrogen in women. After being taken into a woman's body, the conjugated estrogens of Premarin are converted to the active unconjugated estrogens or excreted from the woman's body. Estrone can be converted to estradiol, which is thought to be the major active estrogen in women. [Wikipedia]

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

1,3,5,7-Estratetraen-3-ol-17-one

7-Dehydroestrone

Dihydroequilenin

Equilin

External IDs

Not Available

Product Ingredients

Not Available

Approved Prescription Products

Not Available

Approved Generic Prescription Products

Not Available

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Not Available

Brand mixtures

Not Available

Categories

UNII

08O86EX0J4

CAS number

474-86-2

Weight

Average: 268.3502
Monoisotopic: 268.146329884

Chemical Formula

C₁₈H₂₀O₂

InChI Key

WKRLQDKEXYKHJB-HFTRVMKXSA-N

InChI

InChI=1S/C18H20O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3-5,10,14,16,19H,2,6-9H2,1H3/t14-,16+,18+/m1/s1

IUPAC Name

(1S,11S,15S)-5-hydroxy-15-methyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-2(7),3,5,9-tetraen-14-one

SMILES

[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])C3=C(CC=C21)C=C(O)C=C3

Pharmacology

Indication

For the treatment of moderate to severe vasomotor symptoms associated with the menopause, atrophic vaginitis, osteoporosis, hypoestrogenism due to hypogonadism, castration, primary ovarian failure, breast cancer (for palliation only), and Advanced androgen-dependent carcinoma of the prostate (for palliation only)

Structured Indications

Not Available

Pharmacodynamics

Equilin is a component of Premarin (conjugated estrogens), a mixture of the water soluble salts of sulfate esters from estrone, equilin, 17 alpha-dihydroequilin, and other related steroids, may be derived from pregnant equine urine or yam and soy plants. Estrogens are important in the development and maintenance of the female reproductive system and secondary sex characteristics. They promote growth and development of the vagina, uterus, and fallopian tubes, and enlargement of the breasts. Indirectly, they contribute to the shaping of the skeleton, maintenance of tone and elasticity of urogenital structures, changes in the epiphyses of the long bones that allow for the pubertal growth spurt and its termination, growth of axillary and pubic hair, and pigmentation of the nipples and genitals. Decline of estrogenic activity at the end of the menstrual cycle can bring on menstruation, although the cessation of progesterone secretion is the most important factor in the mature ovulatory cycle. However, in the preovulatory or nonovulatory cycle, estrogen is the primary determinant in the onset of menstruation. Estrogens also affect the release of pituitary gonadotropins. The pharmacologic effects of conjugated estrogens are similar to those of endogenous estrogens.

Mechanism of action

Estrogens enter the cells of responsive tissues (e.g., female organs, breasts, hypothalamus, pituitary) where they interact with a protein receptor, subsequently increasing the rate of synthesis of DNA, RNA, and some proteins. Estrogens decrease the secretion of gonadotropin-releasing hormone by the hypothalamus, reducing the secretion of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the pituitary.

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
Estradiol 17-beta-dehydrogenase 1	Protein	unknown	Not Available	Human	P14061	details
Estrogen receptor	Protein	unknown	Not Available	Human	P03372	details

Absorption

Well absorbed.

Volume of distribution

Not Available

Protein binding

90% bound to plasma proteins

Metabolism

Hepatic

Route of elimination

Not Available

Half life

Not Available

Clearance

Not Available

Toxicity

Not Available

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
1,10-Phenanthroline	The risk or severity of adverse effects can be increased when Equilin is combined with 1,10-Phenanthroline.	Experimental
Aceclofenac	The risk or severity of adverse effects can be increased when Aceclofenac is combined with Equilin.	Approved
Acetylsalicylic acid	The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Equilin.	Approved, Vet Approved
Adapalene	The risk or severity of adverse effects can be increased when Adapalene is combined with Equilin.	Approved
Aldesleukin	Equilin may decrease the antineoplastic activities of Aldesleukin.	Approved
Aluminum hydroxide	The bioavailability of Equilin can be decreased when combined with Aluminum hydroxide.	Approved
Ambenonium	The risk or severity of adverse effects can be increased when Equilin is combined with Ambenonium.	Approved
Aminosalicylic Acid	The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Equilin.	Approved
Amiodarone	The serum concentration of Equilin can be increased when it is combined with Amiodarone.	Approved, Investigational
Amphotericin B	Equilin may increase the hypokalemic activities of Amphotericin B.	Approved, Investigational
Andrographolide	The risk or severity of adverse effects can be increased when HMPL-004 is combined with Equilin.	Investigational
Anisodamine	The risk or severity of adverse effects can be increased when Anisodamine is combined with Equilin.	Investigational
Antipyrine	The risk or severity of adverse effects can be increased when Antipyrine is combined with Equilin.	Approved
Apocynin	The risk or severity of adverse effects can be increased when Acetovanillone is combined with Equilin.	Investigational
Apremilast	The risk or severity of adverse effects can be increased when Apremilast is combined with Equilin.	Approved, Investigational
Aprepitant	The serum concentration of Equilin can be increased when it is combined with Aprepitant.	Approved, Investigational
Atazanavir	The serum concentration of Equilin can be increased when it is combined with Atazanavir.	Approved, Investigational
Atracurium besylate	Atracurium besylate may increase the adverse neuromuscular activities of Equilin.	Approved
Azapropazone	The risk or severity of adverse effects can be increased when Azapropazone is combined with Equilin.	Withdrawn
Azelastine	The risk or severity of adverse effects can be increased when Azelastine is combined with Equilin.	Approved
Balsalazide	The risk or severity of adverse effects can be increased when Balsalazide is combined with Equilin.	Approved, Investigational
Bazedoxifene	The serum concentration of Equilin can be increased when it is combined with Bazedoxifene.	Approved, Investigational
Bendroflumethiazide	Equilin may increase the hypokalemic activities of Bendroflumethiazide.	Approved
Benoxaprofen	The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Equilin.	Withdrawn
Benzoic Acid	The therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Equilin.	Approved
Betulinic Acid	The risk or severity of adverse effects can be increased when Betulinic Acid is combined with Equilin.	Investigational
Bismuth Subcitrate	The bioavailability of Equilin can be decreased when combined with Bismuth Subcitrate.	Approved
Boceprevir	The serum concentration of Equilin can be increased when it is combined with Boceprevir.	Approved, Investigational
Bromfenac	The risk or severity of adverse effects can be increased when Bromfenac is combined with Equilin.	Approved
Bucillamine	The risk or severity of adverse effects can be increased when Bucillamine is combined with Equilin.	Investigational
Bumetanide	Equilin may increase the hypokalemic activities of Bumetanide.	Approved
Calcitriol	The therapeutic efficacy of Calcitriol can be decreased when used in combination with Equilin.	Approved, Nutraceutical
Calcium Carbonate	The bioavailability of Equilin can be decreased when combined with Calcium carbonate.	Approved
Carbamazepine	The serum concentration of Equilin can be decreased when it is combined with Carbamazepine.	Approved, Investigational
Carprofen	The risk or severity of adverse effects can be increased when Carprofen is combined with Equilin.	Approved, Vet Approved, Withdrawn
Castanospermine	The risk or severity of adverse effects can be increased when Castanospermine is combined with Equilin.	Experimental
Celecoxib	The risk or severity of adverse effects can be increased when Celecoxib is combined with Equilin.	Approved, Investigational
Ceritinib	Equilin may increase the hyperglycemic activities of Ceritinib.	Approved
Chloroquine	The risk or severity of adverse effects can be increased when Chloroquine is combined with Equilin.	Approved, Vet Approved
Chlorothiazide	Equilin may increase the hypokalemic activities of Chlorothiazide.	Approved, Vet Approved
Chlorotrianisene	The serum concentration of Equilin can be increased when it is combined with Chlorotrianisene.	Withdrawn
Chlorthalidone	Equilin may increase the hypokalemic activities of Chlorthalidone.	Approved
Cholestyramine	Cholestyramine can cause a decrease in the absorption of Equilin resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Choline magnesium trisalicylate	The risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Equilin.	Approved
Cinoxacin	The risk or severity of adverse effects can be increased when Equilin is combined with Cinoxacin.	Approved, Withdrawn
Ciprofloxacin	The risk or severity of adverse effects can be increased when Equilin is combined with Ciprofloxacin.	Approved, Investigational
Clarithromycin	The serum concentration of Equilin can be increased when it is combined with Clarithromycin.	Approved
Clonixin	The risk or severity of adverse effects can be increased when Clonixin is combined with Equilin.	Approved
Cobicistat	The serum concentration of Equilin can be increased when it is combined with Cobicistat.	Approved
Colesevelam	Colesevelam can cause a decrease in the absorption of Equilin resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Colestipol	Colestipol can cause a decrease in the absorption of Equilin resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Conjugated estrogens	The serum concentration of Equilin can be increased when it is combined with Conjugated Equine Estrogens.	Approved
Corticorelin ovine triflutate	The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Equilin.	Approved
Curcumin	The risk or severity of adverse effects can be increased when Curcumin is combined with Equilin.	Investigational
Darunavir	The serum concentration of Equilin can be increased when it is combined with Darunavir.	Approved
Decamethonium	The risk or severity of adverse effects can be increased when Equilin is combined with Decamethonium.	Approved
Deferasirox	The risk or severity of adverse effects can be increased when Equilin is combined with Deferasirox.	Approved, Investigational
Demecarium	The risk or severity of adverse effects can be increased when Equilin is combined with Demecarium.	Approved
Diclofenac	The risk or severity of adverse effects can be increased when Diclofenac is combined with Equilin.	Approved, Vet Approved
Dienestrol	The serum concentration of Equilin can be increased when it is combined with Dienestrol.	Approved
Diethylstilbestrol	The serum concentration of Equilin can be increased when it is combined with Diethylstilbestrol.	Approved
Diflunisal	The risk or severity of adverse effects can be increased when Diflunisal is combined with Equilin.	Approved
Dihydrotestosterone	Equilin may increase the fluid retaining activities of Dihydrotestosterone.	Illicit
Donepezil	The risk or severity of adverse effects can be increased when Equilin is combined with Donepezil.	Approved
Droxicam	The risk or severity of adverse effects can be increased when Droxicam is combined with Equilin.	Approved
Duvelisib	The risk or severity of adverse effects can be increased when Duvelisib is combined with Equilin.	Investigational
E-6201	The risk or severity of adverse effects can be increased when E6201 is combined with Equilin.	Investigational
Ebselen	The risk or severity of adverse effects can be increased when Ebselen is combined with Equilin.	Investigational
Echothiophate	The risk or severity of adverse effects can be increased when Equilin is combined with Echothiophate.	Approved
Edrophonium	The risk or severity of adverse effects can be increased when Equilin is combined with Edrophonium.	Approved
Enoxacin	The risk or severity of adverse effects can be increased when Equilin is combined with Enoxacin.	Approved
Enzalutamide	The serum concentration of Equilin can be decreased when it is combined with Enzalutamide.	Approved
Epirizole	The risk or severity of adverse effects can be increased when Epirizole is combined with Equilin.	Approved
Equol	The serum concentration of Equilin can be increased when it is combined with S Equol.	Investigational
Estradiol	The serum concentration of Equilin can be increased when it is combined with Estradiol.	Approved, Investigational, Vet Approved
Estriol	The serum concentration of Equilin can be increased when it is combined with Estriol.	Approved, Vet Approved
Estrone	The serum concentration of Equilin can be increased when it is combined with Estrone.	Approved
Etacrynic acid	Equilin may increase the hypokalemic activities of Etacrynic acid.	Approved
Etanercept	The risk or severity of adverse effects can be increased when Etanercept is combined with Equilin.	Approved, Investigational
Ethinyl Estradiol	The serum concentration of Equilin can be increased when it is combined with Ethinyl Estradiol.	Approved
Etodolac	The risk or severity of adverse effects can be increased when Etodolac is combined with Equilin.	Approved, Investigational, Vet Approved
Etofenamate	The risk or severity of adverse effects can be increased when Etofenamate is combined with Equilin.	Approved
Etoricoxib	The risk or severity of adverse effects can be increased when Etoricoxib is combined with Equilin.	Approved, Investigational
Fenbufen	The risk or severity of adverse effects can be increased when Fenbufen is combined with Equilin.	Approved
Fenoprofen	The risk or severity of adverse effects can be increased when Fenoprofen is combined with Equilin.	Approved
Fleroxacin	The risk or severity of adverse effects can be increased when Equilin is combined with Fleroxacin.	Approved
Floctafenine	The risk or severity of adverse effects can be increased when Floctafenine is combined with Equilin.	Approved, Withdrawn
Flumequine	The risk or severity of adverse effects can be increased when Equilin is combined with Flumequine.	Withdrawn
Fluoxymesterone	Equilin may increase the fluid retaining activities of Fluoxymesterone.	Approved, Illicit
Flurbiprofen	The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Equilin.	Approved, Investigational
Fosaprepitant	The serum concentration of Equilin can be increased when it is combined with Fosaprepitant.	Approved
Fosphenytoin	The serum concentration of Equilin can be decreased when it is combined with Fosphenytoin.	Approved
Furosemide	Equilin may increase the hypokalemic activities of Furosemide.	Approved, Vet Approved
G17DT	The risk or severity of adverse effects can be increased when Equilin is combined with G17DT.	Investigational
Galantamine	The risk or severity of adverse effects can be increased when Equilin is combined with Galantamine.	Approved
Gallamine Triethiodide	The risk or severity of adverse effects can be increased when Equilin is combined with Gallamine Triethiodide.	Approved
Gatifloxacin	The risk or severity of adverse effects can be increased when Equilin is combined with Gatifloxacin.	Approved, Investigational
Gemifloxacin	The risk or severity of adverse effects can be increased when Equilin is combined with Gemifloxacin.	Approved, Investigational
Genistein	The serum concentration of Equilin can be increased when it is combined with Genistein.	Investigational
Ginkgo biloba	The risk or severity of adverse effects can be increased when Equilin is combined with Ginkgo biloba.	Approved, Nutraceutical
Glycerol Phenylbutyrate	The therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Equilin.	Approved
Grepafloxacin	The risk or severity of adverse effects can be increased when Equilin is combined with Grepafloxacin.	Withdrawn
Hexestrol	The serum concentration of Equilin can be increased when it is combined with Hexestrol.	Withdrawn
Higenamine	The risk or severity of adverse effects can be increased when Higenamine is combined with Equilin.	Investigational
Huperzine A	The risk or severity of adverse effects can be increased when Equilin is combined with Huperzine A.	Investigational
Hyaluronidase	The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Equilin.	Approved, Investigational
Hydrochlorothiazide	Equilin may increase the hypokalemic activities of Hydrochlorothiazide.	Approved, Vet Approved
Hydroflumethiazide	Equilin may increase the hypokalemic activities of Hydroflumethiazide.	Approved
Ibuprofen	The risk or severity of adverse effects can be increased when Ibuprofen is combined with Equilin.	Approved
Ibuproxam	The risk or severity of adverse effects can be increased when Ibuproxam is combined with Equilin.	Withdrawn
Icatibant	The risk or severity of adverse effects can be increased when Icatibant is combined with Equilin.	Approved
Idelalisib	The serum concentration of Equilin can be increased when it is combined with Idelalisib.	Approved
Indacaterol	Indacaterol may increase the hypokalemic activities of Equilin.	Approved
Indapamide	Equilin may increase the hypokalemic activities of Indapamide.	Approved
Indinavir	The serum concentration of Equilin can be increased when it is combined with Indinavir.	Approved
Indomethacin	The risk or severity of adverse effects can be increased when Indomethacin is combined with Equilin.	Approved, Investigational
Indoprofen	The risk or severity of adverse effects can be increased when Indoprofen is combined with Equilin.	Withdrawn
INGN 201	The risk or severity of adverse effects can be increased when Equilin is combined with INGN 201.	Investigational
INGN 225	The risk or severity of adverse effects can be increased when Equilin is combined with INGN 225.	Investigational
Isoflurophate	The risk or severity of adverse effects can be increased when Equilin is combined with Isoflurophate.	Approved, Withdrawn
Isoniazid	The serum concentration of Isoniazid can be decreased when it is combined with Equilin.	Approved
Isoxicam	The risk or severity of adverse effects can be increased when Isoxicam is combined with Equilin.	Withdrawn
Itraconazole	The serum concentration of Equilin can be increased when it is combined with Itraconazole.	Approved, Investigational
Kebuzone	The risk or severity of adverse effects can be increased when Kebuzone is combined with Equilin.	Experimental
Ketoconazole	The serum concentration of Equilin can be increased when it is combined with Ketoconazole.	Approved, Investigational
Ketoprofen	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Equilin.	Approved, Vet Approved
Ketorolac	The risk or severity of adverse effects can be increased when Ketorolac is combined with Equilin.	Approved
Leflunomide	The risk or severity of adverse effects can be increased when Leflunomide is combined with Equilin.	Approved, Investigational
Levofloxacin	The risk or severity of adverse effects can be increased when Equilin is combined with Levofloxacin.	Approved, Investigational
Lisofylline	The risk or severity of adverse effects can be increased when Lisofylline is combined with Equilin.	Investigational
Lomefloxacin	The risk or severity of adverse effects can be increased when Equilin is combined with Lomefloxacin.	Approved
Lopinavir	The serum concentration of Equilin can be increased when it is combined with Lopinavir.	Approved
Lornoxicam	The risk or severity of adverse effects can be increased when Lornoxicam is combined with Equilin.	Approved
Loxoprofen	The risk or severity of adverse effects can be increased when Loxoprofen is combined with Equilin.	Approved
Lumacaftor	The serum concentration of Equilin can be decreased when it is combined with Lumacaftor.	Approved
Lumiracoxib	The risk or severity of adverse effects can be increased when Lumiracoxib is combined with Equilin.	Approved, Investigational
Magaldrate	The bioavailability of Equilin can be decreased when combined with Magaldrate.	Withdrawn
Magnesium carbonate	The bioavailability of Equilin can be decreased when combined with Magnesium carbonate.	Approved
Magnesium Hydroxide	The bioavailability of Equilin can be decreased when combined with Magnesium hydroxide.	Approved
Magnesium oxide	The bioavailability of Equilin can be decreased when combined with Magnesium oxide.	Approved
Magnesium salicylate	The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Equilin.	Approved
Magnesium Trisilicate	The bioavailability of Equilin can be decreased when combined with Magnesium Trisilicate.	Approved
Malathion	The risk or severity of adverse effects can be increased when Equilin is combined with Malathion.	Approved, Investigational
Masoprocol	The risk or severity of adverse effects can be increased when Masoprocol is combined with Equilin.	Approved
Meclofenamic acid	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Equilin.	Approved, Vet Approved
Mefenamic acid	The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Equilin.	Approved
Mefloquine	The risk or severity of adverse effects can be increased when Equilin is combined with Mefloquine.	Approved
Meloxicam	The risk or severity of adverse effects can be increased when Meloxicam is combined with Equilin.	Approved, Vet Approved
Memantine	The risk or severity of adverse effects can be increased when Equilin is combined with Memantine.	Approved, Investigational
Mesalazine	The risk or severity of adverse effects can be increased when Mesalazine is combined with Equilin.	Approved
Mestranol	The serum concentration of Equilin can be increased when it is combined with Mestranol.	Approved
Metamizole	The risk or severity of adverse effects can be increased when Metamizole is combined with Equilin.	Withdrawn
Methallenestril	The serum concentration of Equilin can be increased when it is combined with Methallenestril.	Experimental
Methanesulfonyl Fluoride	The risk or severity of adverse effects can be increased when Equilin is combined with Methanesulfonyl Fluoride.	Investigational
Methyclothiazide	Equilin may increase the hypokalemic activities of Methyclothiazide.	Approved
Methyltestosterone	Equilin may increase the fluid retaining activities of Methyltestosterone.	Approved
Metolazone	Equilin may increase the hypokalemic activities of Metolazone.	Approved
Mifepristone	The therapeutic efficacy of Equilin can be decreased when used in combination with Mifepristone.	Approved, Investigational
Minaprine	The risk or severity of adverse effects can be increased when Equilin is combined with Minaprine.	Approved
Mitotane	The serum concentration of Equilin can be decreased when it is combined with Mitotane.	Approved
Mivacurium	Mivacurium may increase the adverse neuromuscular activities of Equilin.	Approved
Mizoribine	The risk or severity of adverse effects can be increased when Mizoribine is combined with Equilin.	Investigational
Moxifloxacin	The risk or severity of adverse effects can be increased when Equilin is combined with Moxifloxacin.	Approved, Investigational
Mycophenolate mofetil	The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Equilin.	Approved, Investigational
Mycophenolic acid	The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Equilin.	Approved
Nabumetone	The risk or severity of adverse effects can be increased when Nabumetone is combined with Equilin.	Approved
Nafamostat	The risk or severity of adverse effects can be increased when Nafamostat is combined with Equilin.	Approved, Investigational
Naftifine	The risk or severity of adverse effects can be increased when Naftifine is combined with Equilin.	Approved
Nalidixic Acid	The risk or severity of adverse effects can be increased when Equilin is combined with Nalidixic Acid.	Approved
Naproxen	The risk or severity of adverse effects can be increased when Naproxen is combined with Equilin.	Approved, Vet Approved
NCX 4016	The risk or severity of adverse effects can be increased when NCX 4016 is combined with Equilin.	Investigational
Nefazodone	The serum concentration of Equilin can be increased when it is combined with Nefazodone.	Approved, Withdrawn
Nelfinavir	The serum concentration of Equilin can be increased when it is combined with Nelfinavir.	Approved
Neostigmine	The risk or severity of adverse effects can be increased when Equilin is combined with Neostigmine.	Approved, Vet Approved
Nepafenac	The risk or severity of adverse effects can be increased when Nepafenac is combined with Equilin.	Approved
Nevirapine	The serum concentration of Equilin can be decreased when it is combined with Nevirapine.	Approved
Nicorandil	The risk or severity of adverse effects can be increased when Equilin is combined with Nicorandil.	Approved
Niflumic Acid	The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Equilin.	Approved
Nimesulide	The risk or severity of adverse effects can be increased when Nimesulide is combined with Equilin.	Approved, Withdrawn
Nitroaspirin	The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Equilin.	Investigational
Norfloxacin	The risk or severity of adverse effects can be increased when Equilin is combined with Norfloxacin.	Approved
Ofloxacin	The risk or severity of adverse effects can be increased when Equilin is combined with Ofloxacin.	Approved
Olopatadine	The risk or severity of adverse effects can be increased when Olopatadine is combined with Equilin.	Approved
Olsalazine	The risk or severity of adverse effects can be increased when Olsalazine is combined with Equilin.	Approved
Oxandrolone	Equilin may increase the fluid retaining activities of Oxandrolone.	Approved, Investigational
Oxaprozin	The risk or severity of adverse effects can be increased when Oxaprozin is combined with Equilin.	Approved
Oxymetholone	Equilin may increase the fluid retaining activities of Oxymetholone.	Approved, Illicit
Oxyphenbutazone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Equilin.	Withdrawn
Parecoxib	The risk or severity of adverse effects can be increased when Parecoxib is combined with Equilin.	Approved
Pazufloxacin	The risk or severity of adverse effects can be increased when Equilin is combined with Pazufloxacin.	Investigational
Pefloxacin	The risk or severity of adverse effects can be increased when Equilin is combined with Pefloxacin.	Approved
Pentobarbital	The serum concentration of Equilin can be decreased when it is combined with Pentobarbital.	Approved, Vet Approved
Phenobarbital	The serum concentration of Equilin can be decreased when it is combined with Phenobarbital.	Approved
Phenylacetic acid	The therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Equilin.	Approved
Phenylbutazone	The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Equilin.	Approved, Vet Approved
Phenylbutyric acid	The therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Equilin.	Approved, Investigational
Phenytoin	The serum concentration of Equilin can be decreased when it is combined with Phenytoin.	Approved, Vet Approved
Physostigmine	The risk or severity of adverse effects can be increased when Equilin is combined with Physostigmine.	Approved
Pimecrolimus	The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Equilin.	Approved, Investigational
Piretanide	Equilin may increase the hypokalemic activities of Piretanide.	Experimental
Pirfenidone	The risk or severity of adverse effects can be increased when Pirfenidone is combined with Equilin.	Investigational
Piroxicam	The risk or severity of adverse effects can be increased when Piroxicam is combined with Equilin.	Approved, Investigational
Polythiazide	Equilin may increase the hypokalemic activities of Polythiazide.	Approved
Posaconazole	The serum concentration of Equilin can be increased when it is combined with Posaconazole.	Approved, Investigational, Vet Approved
Primidone	The serum concentration of Equilin can be decreased when it is combined with Primidone.	Approved, Vet Approved
Promestriene	The serum concentration of Equilin can be increased when it is combined with Promestriene.	Investigational
Propacetamol	The risk or severity of adverse effects can be increased when Propacetamol is combined with Equilin.	Approved
Prulifloxacin	The risk or severity of adverse effects can be increased when Equilin is combined with Prulifloxacin.	Investigational
PTC299	The risk or severity of adverse effects can be increased when PTC299 is combined with Equilin.	Investigational
Pyridostigmine	The risk or severity of adverse effects can be increased when Equilin is combined with Pyridostigmine.	Approved
Quinestrol	The serum concentration of Equilin can be increased when it is combined with Quinestrol.	Approved
Quinethazone	Equilin may increase the hypokalemic activities of Quinethazone.	Approved
Rapacuronium	Rapacuronium may increase the adverse neuromuscular activities of Equilin.	Withdrawn
Resveratrol	The risk or severity of adverse effects can be increased when Resveratrol is combined with Equilin.	Experimental, Investigational
Rifabutin	The serum concentration of Equilin can be decreased when it is combined with Rifabutin.	Approved
Rifampicin	The serum concentration of Equilin can be decreased when it is combined with Rifampicin.	Approved
Rifapentine	The serum concentration of Equilin can be decreased when it is combined with Rifapentine.	Approved
Rindopepimut	The risk or severity of adverse effects can be increased when Equilin is combined with CDX-110.	Investigational
Ritonavir	The serum concentration of Equilin can be increased when it is combined with Ritonavir.	Approved, Investigational
Rivastigmine	The risk or severity of adverse effects can be increased when Equilin is combined with Rivastigmine.	Approved, Investigational
Rofecoxib	The risk or severity of adverse effects can be increased when Rofecoxib is combined with Equilin.	Investigational, Withdrawn
Rosoxacin	The risk or severity of adverse effects can be increased when Equilin is combined with Rosoxacin.	Approved
Salicylamide	The risk or severity of adverse effects can be increased when Salicylamide is combined with Equilin.	Approved
Salicylic acid	The risk or severity of adverse effects can be increased when Salicylic acid is combined with Equilin.	Approved, Vet Approved
Salsalate	The risk or severity of adverse effects can be increased when Salsalate is combined with Equilin.	Approved
Saquinavir	The serum concentration of Equilin can be increased when it is combined with Saquinavir.	Approved, Investigational
Secoisolariciresinol	The serum concentration of Equilin can be increased when it is combined with Secoisolariciresinol.	Investigational
Sparfloxacin	The risk or severity of adverse effects can be increased when Equilin is combined with Sparfloxacin.	Approved
SRP 299	The risk or severity of adverse effects can be increased when Equilin is combined with SRP 299.	Investigational
SRT501	The risk or severity of adverse effects can be increased when SRT501 is combined with Equilin.	Investigational
St. John's Wort	The serum concentration of Equilin can be decreased when it is combined with St. John's Wort.	Nutraceutical
Stanozolol	Equilin may increase the fluid retaining activities of Stanozolol.	Approved, Vet Approved
Sulfasalazine	The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Equilin.	Approved
Sulindac	The risk or severity of adverse effects can be increased when Sulindac is combined with Equilin.	Approved
Suprofen	The risk or severity of adverse effects can be increased when Suprofen is combined with Equilin.	Approved, Withdrawn
Synthetic Conjugated Estrogens, A	The serum concentration of Equilin can be increased when it is combined with Synthetic Conjugated Estrogens, A.	Approved
Synthetic Conjugated Estrogens, B	The serum concentration of Equilin can be increased when it is combined with Synthetic Conjugated Estrogens, B.	Approved
Tacrine	The risk or severity of adverse effects can be increased when Equilin is combined with Tacrine.	Withdrawn
Telaprevir	The serum concentration of Telaprevir can be decreased when it is combined with Equilin.	Withdrawn
Telithromycin	The serum concentration of Equilin can be increased when it is combined with Telithromycin.	Approved
Temafloxacin	The risk or severity of adverse effects can be increased when Equilin is combined with Temafloxacin.	Withdrawn
Tenoxicam	The risk or severity of adverse effects can be increased when Tenoxicam is combined with Equilin.	Approved
Teriflunomide	The risk or severity of adverse effects can be increased when Teriflunomide is combined with Equilin.	Approved
Testosterone	Equilin may increase the fluid retaining activities of Testosterone.	Approved, Investigational
Tiaprofenic acid	The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Equilin.	Approved
Tibolone	The serum concentration of Equilin can be increased when it is combined with Tibolone.	Approved
Tinoridine	The risk or severity of adverse effects can be increased when Tinoridine is combined with Equilin.	Investigational
Tolfenamic Acid	The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Equilin.	Approved
Tolmetin	The risk or severity of adverse effects can be increased when Tolmetin is combined with Equilin.	Approved
Torasemide	Equilin may increase the hypokalemic activities of Torasemide.	Approved
Tranilast	The risk or severity of adverse effects can be increased when Tranilast is combined with Equilin.	Approved, Investigational
Trichlormethiazide	Equilin may increase the hypokalemic activities of Trichlormethiazide.	Approved, Vet Approved
Trovafloxacin	The risk or severity of adverse effects can be increased when Equilin is combined with Trovafloxacin.	Approved, Withdrawn
Tubocurarine	The risk or severity of adverse effects can be increased when Equilin is combined with Tubocurarine.	Approved
Valdecoxib	The risk or severity of adverse effects can be increased when Valdecoxib is combined with Equilin.	Investigational, Withdrawn
Voriconazole	The serum concentration of Equilin can be increased when it is combined with Voriconazole.	Approved, Investigational
Warfarin	Equilin may increase the anticoagulant activities of Warfarin.	Approved
Zaltoprofen	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Equilin.	Approved
Zileuton	The risk or severity of adverse effects can be increased when Zileuton is combined with Equilin.	Approved, Investigational, Withdrawn
Zomepirac	The risk or severity of adverse effects can be increased when Zomepirac is combined with Equilin.	Withdrawn

Food Interactions

Not Available

References

Synthesis Reference

Not Available

General References

Sawicki MW, Erman M, Puranen T, Vihko P, Ghosh D: Structure of the ternary complex of human 17beta-hydroxysteroid dehydrogenase type 1 with 3-hydroxyestra-1,3,5,7-tetraen-17-one (equilin) and NADP+. Proc Natl Acad Sci U S A. 1999 Feb 2;96(3):840-5. [PubMed:9927655 ]

External Links

Resource	Link
KEGG Drug	D04041
KEGG Compound	C14392
PubChem Compound	223368
PubChem Substance	46506633
ChemSpider	193995
BindingDB	50423544
ChEBI	42309
ChEMBL	CHEMBL323533
HET	EQI
Wikipedia	Equilin

ATC Codes

Not Available

AHFS Codes

Not Available

PDB Entries

1EQU

FDA label

Not Available

MSDS

Not Available

Clinical Trials

Not Available

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage forms

Not Available

Prices

Not Available

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	239 °C	PhysProp
water solubility	1.41 mg/L (at 25 °C)	YALKOWSKY,SH & DANNENFELSER,RM (1992)

Predicted Properties

Property	Value	Source
Water Solubility	0.0133 mg/mL	ALOGPS
logP	3.8	ALOGPS
logP	3.9	ChemAxon
logS	-4.3	ALOGPS
pKa (Strongest Acidic)	9.41	ChemAxon
pKa (Strongest Basic)	-6	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	2	ChemAxon
Hydrogen Donor Count	1	ChemAxon
Polar Surface Area	37.3 Å²	ChemAxon
Rotatable Bond Count	0	ChemAxon
Refractivity	79.93 m³·mol^-1	ChemAxon
Polarizability	30.55 Å³	ChemAxon
Number of Rings	4	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	Yes	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	1.0
Blood Brain Barrier	+	0.9192
Caco-2 permeable	+	0.875
P-glycoprotein substrate	Substrate	0.6807
P-glycoprotein inhibitor I	Non-inhibitor	0.8085
P-glycoprotein inhibitor II	Non-inhibitor	0.8881
Renal organic cation transporter	Non-inhibitor	0.6704
CYP450 2C9 substrate	Non-substrate	0.7245
CYP450 2D6 substrate	Non-substrate	0.9081
CYP450 3A4 substrate	Substrate	0.7666
CYP450 1A2 substrate	Inhibitor	0.9108
CYP450 2C9 inhibitor	Non-inhibitor	0.9071
CYP450 2D6 inhibitor	Non-inhibitor	0.9231
CYP450 2C19 inhibitor	Inhibitor	0.8209
CYP450 3A4 inhibitor	Non-inhibitor	0.8156
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.5528
Ames test	Non AMES toxic	0.9109
Carcinogenicity	Non-carcinogens	0.93
Biodegradation	Not ready biodegradable	0.9319
Rat acute toxicity	1.8021 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.7619
hERG inhibition (predictor II)	Non-inhibitor	0.601

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum Type	Description	Splash Key
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available
MS	Mass Spectrum (Electron Ionization)	splash10-014i-3940000000-b80393e552aa78600070	View in MoNA
1D NMR	13C NMR Spectrum	Not Available

Taxonomy

Description

This compound belongs to the class of chemical entities known as oxosteroids. These are steroid derivatives carrying a C=O group attached to steroid skeleton.

Kingdom

Chemical entities

Super Class

Organic compounds

Class

Lipids and lipid-like molecules

Sub Class

Steroids and steroid derivatives

Direct Parent

Oxosteroids

Alternative Parents

3-hydroxy delta-7-steroids / 17-oxosteroids / Delta-7-steroids / Phenanthrenes and derivatives / Naphthalenes / 1-hydroxy-2-unsubstituted benzenoids / Ketones / Organic oxides / Hydrocarbon derivatives

Substituents

3-hydroxy-delta-7-steroid / 3-hydroxysteroid / Hydroxysteroid / Oxosteroid / 17-oxosteroid / Delta-7-steroid / Phenanthrene / Naphthalene / 1-hydroxy-2-unsubstituted benzenoid / Benzenoid

Molecular Framework

Aromatic homopolycyclic compounds

External Descriptors

17-oxo steroid, 3-hydroxy steroid (CHEBI:42309 ) / Estrane and derivatives (C14392 ) / C18 steroids (estrogens) and derivatives (LMST02010026 )

Targets

Details

1. Estradiol 17-beta-dehydrogenase 1

Kind: Protein
Organism: Human
Pharmacological action: unknown

General Function:: Testosterone dehydrogenase (nad+) activity
Specific Function:: Favors the reduction of estrogens and androgens. Also has 20-alpha-HSD activity. Uses preferentially NADH.
Gene Name:: HSD17B1
Uniprot ID:: P14061
Molecular Weight:: 34949.715 Da

References

Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]

Details

2. Estrogen receptor

Kind: Protein
Organism: Human
Pharmacological action: unknown

General Function:: Zinc ion binding
Specific Function:: Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription fact...
Gene Name:: ESR1
Uniprot ID:: P03372
Molecular Weight:: 66215.45 Da

References

Starcevic S, Brozic P, Turk S, Cesar J, Rizner TL, Gobec S: Synthesis and biological evaluation of (6- and 7-phenyl) coumarin derivatives as selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2011 Jan 13;54(1):248-61. doi: 10.1021/jm101104z. Epub 2010 Dec 7. [PubMed:21138273 ]

Drug created on June 13, 2005 07:24 / Updated on July 18, 2017 17:06

Get DrugBank to go!

Structure for DB02187 (Equilin)

Targets

References

References